IVF News & Events

INVO Fertility announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a fertility clinic serving patients across Indiana and the broader Midwest. The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025

INVO Fertility announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell device. The patent became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040. "We are pleased to see our previously announced patent allowance conclude with this official issuance, which marks an important milestone for INVO Fertility as we continue to strengthen the intellectual property foundation around the INVOcell platform," said Steve Shum, CEO of INVO Fertility. "INVOcell provides an additional treatment method in the fertility market, enabling fertilization and early embryo development to occur within the patient's body rather than a traditional laboratory incubator. This expanded IP coverage supports our growth strategy and our mission to deliver high-quality fertility care through ongoing innovation."

INVO Fertility issued a shareholder letter from its Chief Executive Officer, Steve Shum, outlining the Company's strengthened fundamental position and its strategic outlook for continued growth. "As we reflect on the progress of INVO Fertility and look ahead to the opportunities before us, we believe our company is in the strongest fundamental position in its history... Over the past several years, our team has worked deliberately to stabilize the business, strengthen the balance sheet, and build a scalable clinical platform capable of sustainable growth... At the core of our progress is the strength of our operating platform. INVO Fertility now has three operational fertility clinics, creating positive operational cash flow and demonstrating the effectiveness of our clinical, operational, and patient-centric model... In addition to our existing footprint, we are nearing the closing on the acquisition of our fourth clinic in Indianapolis... Before factoring in additional organic growth-which we expect to achieve this year-the combined pro forma annualized revenue run rate from all clinics, including both consolidated and equity method clinics, is approximately $9 million inclusive of Indianapolis... Organic growth remains a central component of our strategy... Looking ahead, we anticipate strong growth in 2026, driven by a combination of acquisitions and continued organic expansion... During the past year, we took important steps to simplify and strengthen our capital structure... We believe we are now well positioned to execute our growth objectives this year, without compromising financial discipline. Our focus remains on building a durable, scalable platform that can support sustained growth over time... As we look to the future, we are optimistic about what lies ahead. With a strong operational foundation, a growing clinic network, a robust acquisition pipeline, and the strongest balance sheet we have had in years, INVO Fertility is well positioned for the next chapter of its growth."